Company: CDT
Filing Date: 2025-04-22
Form Type: S-3
Source: 0001641172-25-005732
Chunk: 36

Company: CDT Equity Inc.
Filing Date: 2025-04-22
Form: S-3
Chunk 36
---
                                                                   |
| 4.2     |     | Specimen Warrant Certificate of Conduit Pharmaceuticals Inc. (filed as Exhibit 4.9 to the Registrant’s Amendment No. 3 to Registration Statement on Form S-4 (File No. 333-271903) filed on August 8, 2023 and incorporated herein by reference).                                                                         |
| 10.1*   |     | Consulting Agreement, dated March 25, 2025, by and between the Company and Thesprogen, PC.                                                                                                                                                                                                                                |
| 10.2    |     | Additional Agreement dated March 31, 2025, by and between the Company and Sarborg Limited (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on April 16, 2025 and incorporated herein by reference).                                                                                            |
| 5.1*    |     | Opinion of Thompson Hine LLP                                                                                                                                                                                                                                                                                              |
| 23.1*   |     | Consent of Thompson Hine LLP (included in Exhibit 5.1)                                                                                                                                                                                                                                                                    |
| 23.2*   |     | Consent of Marcum LLP, Independent Registered Public Accounting Firm                                                                                                                                                                                                                                                      |
| 24.1    |     | Power of Attorney (included on signature page)                                                                                                                                                                                                                                                                            |
| 107*    |     | Filing Fee Table                                                                                                                                                                                                                                                                                                          |

*Filed herewith

| II-8 |

<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Naples, State of Florida, on April 22, 2025.

| CONDUIT              
 PHARMACEUTICALS INC. |                   |
| By:                  | /s/               
 Andrew Regan      |
| Name:                | Andrew            
 Regan             |
| Title:               | Chief             
 Executive Officer |

| II-9 |

<div align='center'>POWER OF ATTORNEY</div>

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Andrew Regan and/or James Bligh, as his true and lawful agent, proxy and attorney-in-fact,